Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine

Migraine Clinical Trial

Official title:

A Randomized, Single-Blind Pilot Study to Compare the Efficacy and Cost-Effectiveness of Frovatriptan vs. Topiramate for the Prevention of Migraine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00846495
• Other study ID #: Frova vs. Topiramate
• Status: Completed
• Phase: Phase 4
• First received: February 17, 2009
• Last updated: January 11, 2012
• Start date: August 2009
• Est. completion date: January 2011

Study information

• Verified date: January 2012
• Source: Cady, Roger, M.D.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Subjects enrolled at 2 investigative sites will complete 3 visits. Following Visit 1, during a 1-month Baseline Period, subjects will treat with their usual medication and document any warning signs (Prodrome pre-headache) that a migraine will occur. Following randomization (like a flip of the coin) at Visit 2, subjects will treat daily with topiramate or during Prodrome with frovatriptan. Subjects complete a 2-month Treatment Period before exit at Visit 3.This study will compare the effectiveness of daily treatment vs. treatment during the pre-headache phase for prevention of migraine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: January 2011
• Est. primary completion date: January 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

INCLUSION CRITERIA

1. Subject has at least a one-year history of migraine with or without aura meeting International Headache Society criteria (see Appendix)

2. Subject has a 3-month history of averaging 3-6 migraines per month

3. Subject reports premonitory symptoms and the ability to predict at least 50% of high impact headaches

4. Subjects must currently or have in the past successfully utilized a triptan as an acute treatment for migraine as determined by the investigator.

5. Male or female at least 18 years of age

6. Subject of childbearing potential agrees to use adequate contraception during the study. Adequate methods of contraception are to be determined by the investigator and should be consistent with contraceptive care administered in the regular clinical use of frovatriptan and topiramate.

7. Subject is aware of prodrome symptoms that may include physiological, psychological or cognitive changes. These may include, but are not limited to such symptoms as Pre-Menstrual Syndrome (PMS), change in mood, energy level, appetite, food craving, nausea, sense of hearing, sense of smell or swelling/fluid retention, excessive yawning, head pain, muscle pain/tenderness, irritability, confusion, extreme sleepiness, impaired speech or impaired memory. (The subject should be able to differentiate these symptoms from other similar symptoms that do not precede migraine). The symptoms should precede migraine by 4-24 hours signaling an impending migraine attack.

8. Subject is able to understand instructions for the study and complete the diary

9. Subject is willing to give informed consent to participate in the study

10. Any migraine prophylactic medication must have a stabilized dosage for one month

EXCLUSION CRITERIA

1. History of any medical condition that would confound the results of the study including but not limited to the following:

• Hepatic disease or significant hepatic dysfunction

• History of pancreatitis

• History of thrombocytopenia

• History of glaucoma

• History of osteoporosis or osteopenia

• Cardiovascular Disease - Coronary artery disease, Ischemic heart disease or Significant Arrhythmia

• History of active Cerebrovascular Disease

• Hypertension - Uncontrolled hypertension in a non-migrainous state (> 160 mmHg systolic or >95 mmHg. diastolic). Hypertension must be controlled effectively with medication for a period of 3 months.

• Basilar or Hemiplegic Migraine

• Significant peripheral vascular disease or Raynaud's Syndrome

• Significant Active Renal, Hepatic, Gastrointestinal, Endocrine or

• Neurological Disease

• History of depression, mood problems or suicidal thoughts or behavior that in the opinion of the Investigator would interfere with participation in the study.

2. History of ergotamine, "triptan", or analgesic abuse within past 3 months

3. History of current or recent drug or alcohol abuse that would interfere with participation in the study.

4. More than 15 headache days per month within past 3 months.

5. Women who are pregnant or breast feeding

6. Subjects with known hypersensitivity or intolerance to topiramate or any triptan-like medication

7. Subject is scheduled for surgical procedure to occur while enrolled in study.that in opinion of the Investigator would interfere with participation in the study.

8. Subject is on a ketogenic diet

9. Participation in another investigative drug study within the previous 30 days

10. Excluded medications: MAO Inhibitors, lithium, methylergonovine, methysergide, ergotamine-containing products, or topiramate daily for migraine prophylaxis.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Drug:
• topiramate
topiramate 25mg 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 2 tabs in PM x 1 week topiramate 25mg 2 tabs in AM / 2 tabs in PM x 5 weeks
• frovatriptan
frovatriptan 5mg tab during premonitory phase of migraine

Locations

Country	Name	City	State
United States	Physician Associates LLC	Oviedo	Florida
United States	Clinvest	Springfield	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
Clinvest	Endo Pharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (1)

Luciani R, Carter D, Mannix L, Hemphill M, Diamond M, Cady R. Prevention of migraine during prodrome with naratriptan. Cephalalgia. 2000 Mar;20(2):122-6. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Migraine Attacks in Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate	Compare number of migraine attacks reported by participants using frovatriptan in a preemptive treatment paradigm vs. daily topiramate during Treatment Period Month 2	Treatment Month 2	No
Primary	Number of Headache Days Reported by Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate to Prevent Migraine	Measure the change in number of headache days between participants using frovatriptan in a preemptive treatment paradigm vs. daily topiramate to prevent migraine	Treatment Month 2	No
Secondary	Number of Headache Days Each Month Following Initiation of Treatment With Study Medication	Measure the change in number of headache days reported by participants during each treatment month following initiation of treatment with study medication	2 Months	No
Secondary	Participants With Greater Than 50% Reduction in Migraine Attacks and Headache Days Per Month Utilizing Each Treatment Paradigm	Compare number of participants with greater than 50% reduction in migraine attacks and headache days from Baseline to Treatment Months 1 and 2	2 Months	No
Secondary	Quality of Life in Subjects Utilizing Each Treatment Paradigm	Quality of Life is measured by the Migraine Specific Quality of Life Questionnaire (MSQ), which includes 3 dimensions: Role Function Restrictive (degree to which performance of daily activities is limited), Role Function Preventive (degree to which performance of daily activities is interrupted), and Emotional Function (frustration and helplessness due to migraine). Scores range from 0 to 100. For each dimension, a higher score indicates a better health status. Participants completed the MSQ at Randomization, and after Treatment Months 1 and 2.	Randomization, End of Treatment Month 1, End of Treatment Month 2	No
Secondary	Participant Satisfaction With Study Medications	Participant satisfaction is measured by the Patient Perception of Migraine Questionnaire (PPMQ). Questions were categorized within 6 dimensions: Efficacy, Functionality, Ease of Use, Cost, Bothersomeness of Side Effects, and Total Score. Scores range from 0 to 100. Higher scores represent better satisfaction.; Participants completed the PPMQ 24 hours following each first dose of frovatriptan.	Treatment Month 2	No
Secondary	Adverse Events Associated With Study Medications	Includes Adverse Events at or above 5% frequency per group.	Treatment Months 1 and 2	Yes
Secondary	Cost of Frovatriptan vs. Topiramate as Preventive Treatment of Migraine	Average cost of study medication taken by each subject. Measured in dollars.	Treatment Months 1 and 2	No